P21 (P021)
Peptide 021; Ac-DGGLAG-NH2 (adamantylated CNTF mimetic); PB021 (Phanes Biotech designation). Synonyms: P-21, CNTF-derived neurotrophic peptide P021. Note: distinct from the p21/CDKN1A cell-cycle protein and from RAS-p21 peptides.
This peptide has not been evaluated by the FDA. It is sold as a research chemical and has no regulatory status for human use.
A synthetic short peptide designed to stimulate new brain cell growth, boost brain-nourishing proteins, and potentially slow Alzheimer's-related damage. All evidence comes from animal studies; no human clinical trials have been completed.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Safety Summary
All side effect data for P021 derives from preclinical rodent studies and anecdotal community reports -- no human clinical trial safety data exists. In chronic rodent studies up to 18 months, no systemic toxicity, weight loss, organ abnormalities, tumor formation, or mortality attributable to P021 was observed, and importantly, P021 did not produce the weight loss/anorexia seen with full-length CNTF. No immunogenicity (anti-drug antibody formation) detected in preclinical studies. No evidence of tolerance, tachyphylaxis, or withdrawal effects in chronic preclinical dosing. No drug-drug interaction studies have been conducted. Because P021 modulates pathways related to cell survival and apoptosis, there is a theoretical risk regarding tumor facilitation, though no cancer signals were seen in 18-month rodent studies. The absence of human safety data is the primary limitation; all frequency estimates are extrapolated from community reports with inherent reporting bias.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-5]